China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first subject dosing in a Phase I clinical study assessing the safety and tolerability of intravitreal injection of IBI333. This recombinant anti-VEGF-A and anti-VEGF-C bispecific antibody (BsAb) was independently developed by Innovent and is being evaluated for the treatment of neovascular age-related macular degeneration (nAMD).
Pathological Mechanism and Current Treatment
The pathological mechanism of AMD has not been fully elucidated, but it is widely recognized that angiogenesis induced by increased VEGF expression is a major cause of nAMD pathogenesis. Intravitreal injection of anti-VEGF agents is currently the standard treatment for nAMD. IBI333 represents a novel approach by simultaneously binding and neutralizing the activities of both VEGF-A and VEGF-C.
IBI333: Mechanism of Action and Potential Benefits
Compared to existing anti-VEGF-A agents, IBI333 can inhibit the compensatory increased activity of VEGF-C, thereby achieving a more comprehensive blockage of the VEGF/VEGFR signaling pathway. This dual-action mechanism implies the potential for more effective inhibition of angiogenesis and reduction of vascular leakage, suggesting that IBI333 could offer a more desirable treatment outcome for patients with nAMD.
Strategic Implications
The initiation of the Phase I clinical study for IBI333 marks a significant step forward in Innovent Biologics’ efforts to develop innovative treatments for ophthalmic conditions. By targeting both VEGF-A and VEGF-C, IBI333 has the potential to address the limitations of current therapies and improve patient outcomes in the treatment of neovascular AMD.-Fineline Info & Tech
